Latest neutropenia Stories
PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc.
WASHINGTON and BERLIN, Feb. 17, 2011 /PRNewswire-USNewswire/ -- President Obama and Chancellor Merkel, "I don't want to die now!" is the urgent plea to two world-leaders from a child who will die without immediate medical intervention and protection.
PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc.
BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S.
MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim(TM).
BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent TaxotereÂ® (docetaxel) Injection Concentrate.
PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.
LEAMINGTON SPA, United Kingdom, June 10 /PRNewswire-FirstCall/ -- Hospira announced today that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1).
CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.